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Abstract
Background: Asthma is a common disease characterised by reversible airflow obstruction, bronchial hyperresponsiveness
and chronic inflammation, which is commonly treated using corticosteroids such as budesonide. MicroRNAs (miRNAs) are a
recently identified family of non-protein encoding genes that regulate protein translation by a mechanism entitled RNA
interference. Previous studies have shown lung-specific miRNA expression profiles, although their importance in regulating
gene expression is unresolved. We determined whether miRNA expression was differentially expressed in mild asthma and
the effect of corticosteroid treatment.
Methodology/Principal Findings: We have examined changes in miRNA using a highly sensitive RT-PCR based approach to
measure the expression of 227 miRNAs in airway biopsies obtained from normal and mild asthmatic patients. We have also
determined whether the anti-inflammatory action of corticosteroids are mediated through miRNAs by determining the profile
of miRNA expression in mild asthmatics, before and following 1 month twice daily treatment with inhaled budesonide.
Furthermore, we have analysed the expression of miRNAs from individual cell populations from the airway and lung. We
found no significant difference in the expression of 227 miRNAs in the airway biopsies obtained from normal and mild
asthmatic patients. In addition, despite improved lung function, we found no significant difference in the miRNA expression
following one month treatment with the corticosteroid, budesonide. However, analysis of bronchial and alveolar epithelial
cells, airway smooth muscle cells, alveolar macrophages and lung fibroblasts demonstrate a miRNA expression profile that is
specific to individual cell types and demonstrates the complex cellular heterogeneity within whole tissue samples.
Conclusions: Changes in miRNA expression do not appear to be involved in the development of a mild asthmatic
phenotype or in the anti-inflammatory action of the corticosteroid budesonide.
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Introduction
T h er e g u l a t i o no fg e n ee x p r e s s i o n is important in maintaining
tissue homeostasis, preventing inflammatory processes and cancer.
Recently, microRNAs (miRNAs) have been shown to regulate gene
expression by inhibiting protein translation. MiRNAs are a family of
small, non-coding RNA molecules that are transcribed in the nucleus
into complex hairpin-loop primary-miRNAs [1]. Theseare processed
by the RNAse III-type enzyme Drosha [2], into precursor-miRNAs,
which are transported into the cytoplasm by the exportin 5 complex
[3]. Further processing by the enzyme dicer results in short double-
stranded miRNAs approximately 22 nt in length [4]. One strand of
the miRNA, referred to as the mature miRNA (the other strand
miRNA
* is generally degraded), is incorporated into a large
ribonucleoprotein (RNP) complex called the miRNA-induced
silencing complex (miRISC), where it binds to its target mRNA
[5,6]. The miRNA:mRNA interaction occurs within the 39-UTR of
the target mRNA at specific miRNA-recognition elements (MREs),
usually in a partially complementary manner [7,8]. The result of
miRNA binding in the miRISC is the inhibition of protein
translation, either through inhibition of translation initiation/
elongation or through mRNA destabilisation [9].
Several human diseases have now been associated with
disregulated miRNA expression. For example, cardiac hypertro-
phy has been linked to an absence of miR-1, while cardiomyocyte
differentiation is regulated by miR-1 through interaction with
serum response factor [10]. Cardiac arrhymogenesis has also been
linked to miR-1, as well as miR-133, both acting through the
regulation of essential ion channel proteins [11]. Metabolic
diseases have been linked to certain miRNAs including the control
of insulin secretion by miR-375 [12] and lipid metabolism in the
liver by miR-122 [13]. Inflammatory diseases are also likely to be
regulated by miRNAs, as miR-203 and miR-146a are associated
with psoriasis [14], while miR-155 regulates lung remodelling
[15]. Both miR-146a and miR-155 have also been implicated in
the development of rheumatoid arthritis, possibly by regulating
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5889components of the inflammatory response [16,17]. Furthermore,
the altered expression of miRNAs has also been associated with
the progression of several cancers, including solid tumours and
leukaemias. For example, overexpression of the miR-17-92 cluster
is thought to influence tumour progression [18], and is controlled
by the transcription factor c-myc [19]. Burkitt’s lymphoma,
Hodgkin’s lymphoma and lung cancer have all been associated
with miR-155 overexpression [20–22], while B cell chronic
lymphocytic leukaemia has been linked to a deletion in the miR-
15/miR-16 locus [23]. More recently, miR-34a has been
demonstrated to be an important component of the p53 network,
probably functioning to reinforce the tumour suppressor effects of
p53 [24,25]. However it is unclear what influence miRNAs have
over other human diseases such as asthma.
Asthma is a chronic inflammatory condition of the airways that
is characterised by airway hyperresponsiveness and intermittent
episodes of wheezing, chest tightness and shortness of breath. It is
usually classified according to its level of severity. We have opted
to study asthma patients classified as having mild asthma who have
normal lung function and using only inhaled short-acting b-
adrenergic agonists as required for relief of asthma symptoms and
not using inhaled corticosteroid therapy [26]. We have avoided
using patients with a more severe category of asthma because these
patients are usually on chronic treatment with inhaled corticoste-
roids and are likely to have an inflammatory infiltrate.
We have previously demonstrated that several miRNAs are
upregulated in response to inflammatory stimuli in mouse models
of inflammation and in human epithelial cell lines [27,28]. We
have also shown that the lung has a very specific miRNA
expression profile, which is conserved across mammalian species,
and that miRNAs are important for lung development and in
maintaining lung homeostasis [29,30].
There were two main objectives of the present study. First, we
compared the microRNA profile of airway biopsies from patients
with mild asthma compared to those from healthy non-asthmatic
volunteers. Second, we examined the effect of treatment with
inhaled corticosteroid therapy over 4 weeks on the microRNA
profile in patients with steroid-naı ¨ve mild asthma. We now report,
for the first time, the specific miRNA expression profile in human
airway biopsies from mild asthmatic patients and in the cell types
commonly associated with the airways and lung. By comparing
airway biopsy samples from asthmatic patients with those of
healthy individuals we observed that this profile is maintained in
the mild asthmatic phenotype. In addition, treatment with the
corticosteroid budesonide did not affect the specific miRNA
expression profile.
Results
MicroRNA expression was not altered in asthmatic
airways
Asthma is an obstructive airway disease characterised by
reversible airways contraction and associated with chronic
inflammation and airway remodelling. All asthmatics had a
positive skin prick test and had an FEV1 (% predicted) of 8364.
During methacholine challenge, these mild asthmatic patients had
aP C 20 of 561 mg/ml (table 1). The second group of patients,
between the ages of 18 and 23 years, had no history of asthma.
These volunteers had an FEV1 (% predicted) of 9564 and failed
to generate a response during methacholine challenge
(PC20.16 mg/ml).
Since miRNAs have been identified as key regulators of
inflammatory, developmental and homeostatic gene expression,
the miRNA expression profile of asthmatic airways was compared
with non-asthmatic in order to identify any changes in miRNA
expression. The expression of 227 miRNAs was analysed by RT-
PCR from each individual biopsy. The expression of each miRNA
was calibrated to the small nucleolar RNA RNU44 (house-keeping
gene) and the relative expression (2
-(DDCT)) calculated using the
standard DCT method and based on the mean expression value of
all 227 miRNAs from each person (figure 1, table S1). An
expression heat map of the data was produced in Genesis software
(Graz University of Technology) and statistical analysis performed
by ANOVA. Of the 227 miRNAs analysed no miRNAs were
differentially expressed in asthmatic samples compared to healthy.
This included those miRNAs that have a relatively high expression
in human airways (2
-(DDCT).10), which are likely to represent
those miRNAs that are expected to have a biological function in
airway cells (figure 2).
Budesonide treatment did not alter the miRNA
expression profile
Corticosteroids are commonly used to suppress the chronic
inflammation underlying asthma. In the five asthmatic patients
who underwent budesonide therapy for 28 days, the mean PC20
increased from 3.762.7 mg/ml to .16 mg/ml, indicating an
improvement in the clinical outcome (table 2).
Considering that budesonide improved the mild asthmatic
phenotype, the miRNA expression profile was compared between
airway biopsy samples from asthmatic patients before and after
budesonide treatment. Of the 227 miRNAs measured using RT-
PCR, there was no alteration in the miRNA expression profile
(figure 3, table S2), with the tissue-specific miRNA expression
profile persisting despite a 4-week long regime of budesonide.
Analysis of microRNA expression profile of human airway
biopsies
The interaction between miRNAs and mRNA are important in
regulating gene expression and maintaining tissue homeostasis. It
is often the case that a diseased phenotype is associated with an
altered miRNA expression profile. Individual tissues and cell types
can also be identified based on their particular miRNA expression
profile and express tissue specific miRNAs. Therefore, the miRNA
expression profile from non-asthmatic, healthy human airways was
analysed in order to identify airway specific miRNAs (n=8). The
expression of 227 miRNAs were ranked from the most highly
expressed to the least expressed and were then grouped into four
separate categories based on their expression levels; high
Table 1. Summary of patient data: healthy versus mild-asthmatic.
n Age (years) Male/female ratio FEV1 (% predicted) PC20 (mg/ml)
Healthy 8 20613 / 5 9 5 64 .16
Asthmatic 8 29631 / 7 8 3 645 61
doi:10.1371/journal.pone.0005889.t001
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-(DDCT).10), moderate expression (2
-(DDCT)=0.5–10),
low expression (2
-(DDCT),0.5) and no expression (not detected)
(figure 4). This analysis revealed that miR-92, miR-26a, miR-
200c, miR-16, let-7b, miR-125a, and miR-125b were the most
highly expressed in human airway tissue, having levels more than
70-fold higher than the average miRNA and contributing 55.5%
of the total mRNA detected in airway biopsies. In addition,
members of the let-7 family (let-7a, let-7b and let-7c), miR-26
family (miR-26a and miR-26b), miR-125 family (miR-125a and
miR-125b) and miR-30 family (miR-30a-5p, miR-30b and miR-
30c) also fell within the highly expressed category and are
therefore considered to be human airway specific (figure 4).
Target prediction and validation for miRNAs is often
problematic due to the number of potential mRNA targets that
current prediction algorithms identify. In order to relate the
specific miRNA expression profile in human airways to potential
mRNAs targets, we analysed all highly expressed miRNAs using
an available public database, Targetscan 4.2 (http://www.
targetscan.org). For each highly expressed miRNA the chromo-
some location, number of potential targets and example targets
(based on those targets that may be involved in signalling
pathways, transcription factors or genes related to airway
structure/function) have been analysed (table S3). In addition,
the transcription factor binding sites that occur within 5 kb
upstream of the miRNA gene start site have been analysed using
the UCSC Genome Browser tool (http://genome.ucsc.edu).
Those miRNAs that were highly expressed were not associated
with a particular chromosomal location; rather they are located at
various sites throughout the genome (table S3). The highly
expressed miRNAs most frequently targeted MAP kinases such as
MAPK6 and MAP4K4 and also pro-collagen transcripts such as
COL1A2, transcripts associated with the translational machinery
such as E2F3, E2F7 and EIF4G2 and transcription factors such as
NFIA, NFIB. The transcription factor binding sites (up to 5 kb
upstream of the miRNA start sites) included sites for FOXO,
PAX5, TAL1 and AREB transcription factors (figure 5).
Cell-specific microRNA expression
In order to determine the expression of miRNAs in isolated cell
types, qRT-PCR was performed on various cell types from the
airways and lungs. The cell types analysed included alveolar
epithelial cells, bronchial epithelial cells, airway smooth muscle
cells, alveolar macrophages and bronchial fibroblasts. The
expression of several miRNAs was also analysed from whole
human lung samples, thus representing a range of cell types that
have critical functions within the airways and lungs. The miRNAs
that were measured were those that had a level of expression 10-
Figure 1. Profile of miRNA expression in control and asthmatic
patients. A panel of 227 individual microRNAs were measured in
airway biopsies obtained from normal and mild asthmatics patients
using semi-quantitative real-time RT-PCR. The DCT method was used to
calculate the relative expression (compared to the mean expression of
all miRNAs measured) of each miRNA (2
-(DCT individual miRNA – mean of 227
miRNAs)) and each sample was normalised to the snoRNA RNU44. Red
indicates an increase in expression and green a decrease in expression
relative to the mean expression of 227 miRNAs. Black means not
detected. During the analysis, care was taken to avoid the detection of
false positive, therefore DCT values less than 37 (that corresponded to
the value of signal from the no-template control) were removed as were
miRNAs that were on the limit of detectability having a sample number
(n) less than n=4. Each column represents an individual biopsy sample
and each row an individual miRNA (mild asthmatic n=8 and healthy
n=8). Statistical analysis on the sample groups was measured in
Genesis using ANOVA with a p-value threshold of 0.05.
doi:10.1371/journal.pone.0005889.g001
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(figure 2).
The relative expression (RU) for each miRNA was calculated
using the DDCT method and the airway samples used as the
calibrator to determine fold-differences in expression (figure 6).
Three miRNAs, miR-375, miR-449 and miR-200c were specif-
ically expressed only in the airway samples. The expression of
miRNAs in epithelial cells was similar to that in whole lung and
included miR-125a, miR-30b/c/d, miR-20d, miR-93 and miR-
26b, although some of the miRNAs were also significantly
expressed in macrophages and fibroblasts (e.g. miR-30c). Two
miRNAs were highly expressed in airway smooth muscle cells,
miR-16 and miR-140. Alveolar macrophages possessed the highest
number of highly expressed miRNAs than the other cell types and
included miR-92, miR-223, miR-191, miR-30a-5p, miR-320,
miR-342, miR-146b and miR-142-3p. Those miRNAs that were
dominant in lung fibroblasts were let-7b, let-7c, miR-214, miR-
125b and miR-222, while the remaining miRNAs demonstrated a
more general expression pattern across most cell types (figure 6).
Discussion
MicroRNAs are a recently discovered family of non-coding
RNA molecules that post-transcriptionally regulate gene expres-
sion. They are endogenously expressed as primary-miRNAs and
are processed in the nucleus and cytoplasm to form ,22 nt
double-stranded miRNAs. Only one strand of the miRNA is
incorporated into a ribonucleoprotein complex called the
miRISC, where it binds to its target mRNA and either prevents
protein translation or initiates mRNA destabilisation. The
regulatory potential of miRNAs is vast when you consider that
most miRNAs are predicted to target many 100s of mRNAs [31].
Although ,700 miRNAs have been identified in the human
genome, the biological function of the majority of these is
unknown. Furthermore, it is unclear as to how miRNAs contribute
to complex diseases such as asthma. To measure the miRNA
expression profile, we used semi-quantitative RT-PCR method
based on highly sensitive TaqMan technology (Applied Biosys-
tems). This allows for small quantities of total RNA to be used for
the measurement of many individual miRNA molecules. This
technique is therefore appropriate for the analysis of small airway
biopsies, which contain small amounts of starting RNA. Of the
227 miRNAs that were measured no differences in expression
levels were observed between healthy and mild asthmatic samples.
Despite the lack of differential expression between healthy and
asthmatic biopsies, this study has revealed a number of important
issues regarding such analysis. The main problem/issue with
analysing the miRNA expression in airway biopsies is the degree of
cellular heterogeneity within each biopsy [32–34]. This has the
potential of masking any differences in the expression of individual
miRNAs within specific cell types. Therefore, there remains the
possibility that differential miRNA expression is occurring in the
airways of mild-asthmatics but within a particular cell type. In
addition, a significant change might be observed by using biopsies
from more severe asthma patients, although interpretation maybe
confounded by the presence of inflammatory cells such as
Figure 2. Highly expressed miRNAs did not alter in mild asthmatic airways. Individual microRNAs were measured in airway biopsies
obtained from normal and mild asthmatics patients using semi-quantitative real-time RT-PCR. The DCT method was used to calculate the relative
expression (compared to the mean expression of all miRNAs measured) of each miRNA (2
-(DCT individual miRNA – mean of 227 miRNAs)) and each sample was
normalised to the snoRNA RNU44. A total of 28 miRNAs had a relative expression value (2
-(DDCT)) greater than 10 and were therefore classified as
being highly expressed.
doi:10.1371/journal.pone.0005889.g002
Table 2. Summary of patient data: mild-asthmatics before and after budesonide treatment.
Budesonide treatment n Age (years) Male/female ratio FEV1 (% predicted) PC20 (mg/ml)
Before 5 29681 / 4 8 9 65 3.762.7
After 5 29681 / 4 8 5 610 .16
doi:10.1371/journal.pone.0005889.t002
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migratory cells that enter sites of inflammation in the airway would
augment the heterogeneity of biopsy samples.
The analysis of individual cell types from the airways and lungs
of humans did indeed reveal that the expression profile of each
miRNA differed significantly depending on the cell type. This
differential expression is an important consideration when
analysing samples such as airway biopsies that have a heteroge-
neous cell population. These findings gave an indication as to
which cell types contributed the most to the overall expression
level of an individual miRNA within the airways, even though all
26 miRNAs were expressed 10-fold or more higher than average.
For example, miR-140 was predominantly expressed in airway
smooth muscle cells. The most prominent cell type was alveolar
macrophages, which possessed a high expression of several
miRNAs including miR-223 and miR-146b, further emphasising
how migratory cells (as well as resident cells) contribute to the
overall miRNA expression profile within a given tissue. These two
miRNAs have previously been shown to be specifically expressed
in myeloid and lymphoid cell lineages [35] and may function as
regulators of the innate immune system [27]. Two miRNAs, miR-
375 and miR-449 were specific only to airway samples, indicating
that these miRNAs are expressed in a cell type that is explicit the
airways.
The use of drugs such as b2 agonists and corticosteroids by these
patients may also interfere with the expression of miRNAs that
may be involved in the pathophysiology of asthma; however, we
examined asthmatics who have never received corticosteroid
therapy for their asthma. The authors also appreciate that despite
the identification of .700 human miRNAs, we were only able to
analysis the expression of 227 miRNAs. This was a result of the
small quantities of RNA that can be obtained from biopsies, which
required the use the RT-PCR based approach. However, the
miRNAs included in the panel represent most of those that were
recently shown to be either ubiquitously expressed or those that
account for most of the differences in miRNA profiles between cell
lineages and tissues [36]. Indeed, this conclusion is demonstrated
in the supplemental Tables where we failed to observe the
expression of the most recently identified miRNAs i.e. miR-500
upwards.
To investigate the effect of inhaled corticosteroids, similar
miRNA expression analysis was performed on asthmatic airway
biopsy samples following budesonide treatment and compared to
pre-treatment samples. We ensured that the patients had
administered the correct dose of inhaled medication by counting
the appropriate number of puffs on the inhaler counter. As a
positive indication that budesonide was correctly administered,
Figure 3. Profile of miRNA expression in asthmatic patients
treated before and following treatment with budesonide. A
panel of 227 individual microRNAs were measured in airway biopsies
obtained from asthmatics patients before and after 28 days treatment
with twice daily inhaled budesonide (200 mg) using semi-quantitative
real-time RT-PCR. The DCT method was used to calculate the relative
expression (compared to the mean expression of all miRNAs measured)
of each miRNA (2
-(DCT individual miRNA – mean of 227 miRNAs)) and each sample
was normalised to the snoRNA RNU44. Red indicates an increase in
expression and green a decrease in expression relative to the mean
expression of 227 miRNAs. Black means not detected. Values with a DCT
value of 37 or greater were removed from the analysis as were miRNAs
at the limit of detection having a sample number less than n=3. Each
column represents an individual biopsy sample and each row an
individual miRNA (n=5 before budesonide and n=5 after budesonide).
Statistical analysis on the sample groups was measured in Genesis using
ANOVA with a p-value threshold of 0.05.
doi:10.1371/journal.pone.0005889.g003
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the normal range, as would be expected with this treatment in
patients with mild asthma [37]. We deliberately chose to study
patients who have not been on treatment with inhaled corticoste-
roids in order to avoid the potential issue of tachyphylaxis to this
treatment. Corticosteroids are potent anti-inflammatory agents
that are known to interfere with a number of intracellular
pathways including transcription factors such as NF-kB and AP-1
and to inhibit many pro-inflammatory cytokines and chemokines
[38,39]. These anti-inflammatory effects of corticosteroids are
likely to underlie the improvement in bronchial hyperresponsive-
ness observed. Despite some of the highly expressed miRNAs
containing NF-kB transcription factor binding sites, no alteration
in miRNA expression was observed following budesonide
treatment. Considering the lack of differential expression of
miRNAs in mild asthmatics, it may be that budesonide does not
exert an action upon basal miRNA expression. Again, perhaps a
severe asthmatic phenotype would reveal the effects of budesonide.
However, our previous studies examining the miRNA expression
in lung tissue from mice challenged with LPS revealed no
detectable effects following treatment with dexamethasone [40].
Expression profiling of human airway biopsies revealed several
highly expressed miRNAs, including miR-92, miR-200c, miR-
26a, miR-16, let-7b, miR-125a and miR-125b, which together
comprised 55.5% of the total miRNA species analysed. These
miRNAs are likely to represent those that have a significant
influence on gene expression in the airways. For instance, miR-26a
has been shown to target the transcription factor SMAD1 during
the differentiation of stem cells [41] and we have previous shown
that this is selectively expressed in the bronchial and alveolar
epithelial cells in mouse lung [28]. SMAD1 is known to be an
important transcription factor for the regulation of bone
morphogenic protein signalling during lung development and
pulmonary vascular remodelling [42,43]. This suggests that miR-
26a might be important in controlling essential developmental and
physiological events in the lung, which may also include
pathological events during pulmonary diseases such as asthma.
Indeed, we have previously demonstrated that it is upregulated in
the adult lung following the postnatal period of lung development
and is highly expressed within bronchial and alveolar epithelial
cells [29]. The rate of apoptosis or proliferation is known to be
regulated by miR-16 and let-7 [23,44] whilst miR-125 is the
mammalian homologue of lin-4, and has previously been shown to
be associated with embryonic development [45]. The development
and maintenance of airway tissue and the regulation of gene
expression in the airway is therefore likely to be under the control
of these miRNAs.
Bioinformatic analysis of the transcription factor binding sites in
the promoter regions located upstream of miRNA start sites,
provides information on which transcription factors are involved
in the regulation of miRNA expression. However, no transcription
factor binding sites were particularly overrepresented in the 59-
regions upstream of the highly expressed miRNA start sites.
Furthermore, the predicted targets of these highly expressed
miRNA may to some extent reveal their biological function. For
example, several MAP kinases were predicted to be targets,
suggesting that these highly expressed miRNAs may be able to
inhibit signalling molecules involved in the inflammatory response.
In conclusion, we showed that changes in miRNA expression
are not associated with the mild asthma phenotype. It is possible
Figure 5. Bioinformatic analysis of highly expressed miRNAs in human airways. The specific miRNA targets were predicted using
Targetscan 4.2. The gene targets for those miRNAs highly expressed in the airway (2
-(DDCT).10). Targets that shared a high frequency across the
miRNAs analysed (28 miRNAs in the highly expressed group) are plotted. Likewise, the transcription factor binding sites within 5 kb of the miRNA
start site, for the same set of miRNAs, were analysed using UCSC Genome Browser. Abbreviations; MAPK, mitogen activated protein kinase; COL,
collagen; EIF, eukaryotic translation initiation factor; SOCS, suppressor of cytokine signalling; IGF, insulin-like growth factor; PCDH, protocadherin.
doi:10.1371/journal.pone.0005889.g005
Figure 4. MicroRNA expression analysis of human airway biopsies. A panel of 227 individual microRNAs were measured using semi-
quantitative real-time RT-PCR on non-asthmatic, healthy human airway biopsy samples (n=8). The DCT method was used to calculate the relative
expression (compared to the mean expression of all miRNAs measured) of each miRNA (2
-(DCT individual miRNA – mean of 227 miRNAs)) and each sample was
normalised to the snoRNA RNU44. Red indicates an increase in expression and green a decrease in expression relative to the mean expression of 227
miRNAs.
doi:10.1371/journal.pone.0005889.g004
MicroRNAs and Mild Asthma
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more severe asthma patients may reveal changes in miRNA
expression. However, these patients are invariably treated with
corticosteroids that may alter miRNA expression. Another
approach would be to study the airways after an allergen challenge
that is known to intensify allergic airway inflammation. We also
found that the anti-inflammatory effects of the corticosteroid
budesonide does not appear to be mediated through changes in
miRNA expression, which may also be due to the mild state of
inflammation in these mild asthma patients.
Materials and Methods
Patient assessment
Eight patients with asthma and eight normal volunteers were
recruited for the study. All patients gave a history of intermittent
wheeze and were only using salbutamol inhaler on an intermittent
basis, less than twice a week, were corticosteroid-naı ¨ve, and all had
positive skin-prick tests to common aeroallergens. These mild
asthmatic patients had a PC20 of 561 mg/ml. The normal
volunteers have never had any history of wheezing or chest
tightness on questioning and all had PC20 to methacholine of
greater than 16 mg/ml, and 3 of the 8 normal subjects had
positive skin prick tests. The asthmatics had an FEV1 of 8364% of
predicted values and the normal volunteers all had FEV1 values
9564% of predicted values. All normal subjects had PC20
methacholine greater than 16 mg/ml. None of the subjects were
or had been cigarette smokers.
Each subject underwent a baseline fiberoptic bronchoscopic
study using topical anesthesia with lidocaine to the upper and
lower airways under sedation with intravenous midazolam (3–
6 mg) and alfentanyl (125 mg). Airway biopsies were taken from
segmental and sub-segmental airways of the right lower lobe and
were then snap-frozen in pre-cooled isopentane in liquid nitrogen
and stored at 270uC. Five of the 8 patients with asthma undertook
to inhale budesonide dry powder from a Pulmicort Turbohaler
R
(200 mg per inhalation; 2 inhalations) twice daily for 4 weeks.
Compliance to treatment was ensured by (i) a phone call to the
subject once a week and by (ii) asking the subject to bring back
their Turbohaler inhaler and making sure that the counter shows
that an appropriate number of puffs had been dispensed. At the
end of 28 days, PC20 to methacholine was measured, fibre-optic
bronchoscopy was repeated and airway biopsies were obtained as
previously described. None of the patients reported any adverse
events during the treatment or the bronchoscopy procedure.
Ethical approval was given by the ethical review committee at
Imperial College London, Royal Brompton Campus and written
consent has been received from all patients involved in the study.
qRT-PCR
The miRNA expression profile for each airway biopsy sampled
was analysed using Applied Biosystems miRNA TaqMan panel of
227 individual miRNAs. The reverse transcription used 2 ng of
starting total RNA for each miRNA assay. Multiplex pools of up to
48 miRNAs were used for the RT reactions according to the
manufacturers’ guidelines (Applied Biosystems). This enables up to
48 miRNAs to be prepared in a single RT reaction. The PCR
reaction comprised 5 ml TaqMan 26Universal PCR Master Mix,
No AmpErase UNG (Applied Biosystems), 3.835 ml RNAse free
water (Promega), 0.5 ml TaqMan probe (Appled Biosystems) plus
0.67 ml RT product and the reaction conditions were 95uC for
10 min and then 40 cycles of 95uC for 10 seconds and 60uC for
1 min. The amount of RNA from each sample was calibrated to
the expression of the small nucleolar RNA RNU44 (house-keeping
gene). This then gave a delta CT (DCT) value for each miRNA
(miRNA CT value – RNU44 CT value). The relative expression
of each miRNA was calculated by comparing each value to the
mean value of all 227 miRNAs. The fold difference in expression
was calculated as 2
-(DCT sample-DCT mean sample). In order to avoid
the possibility of generating false positive values any DCT value of
37 or greater was removed from the data set. This value
corresponded to the sample detection from the no-template
control, a value which falls below the acceptable value of
detection. Furthermore, any miRNA that was on the limit of
detection and having a sample number less than n=4 (or n=3
from the budesonide study) was also removed from further
analysis. Any miRNA that was not detected was regarded as not
being significantly expressed in human airways. The generation of
heat maps for miRNA expression and calculation of statistical
significance was performed using Genesis software (Graz Univer-
sity of Technology) with a p-value threshold of 0.05. Relative
expression of miRNAs from airway biopsies taken from asthmatics
before and after budesonide treatment was also calculated using
the DCT method (normalised to RNU44). False positives were
eliminated as described and the relative expression calculated
using the DCT method.
Bioinformatic analysis of microRNAs
The precise genomic location and nucleotide sequence of each
human miRNA was determined using miRBase (Wellcome Trust
Sanger Institute; http://microrna.sanger.ac.uk). Analysis of miRNA
targets was performed using the public database, Targetscan 4.2
(http://www.targetscan.org). Particular interest was given to tran-
scription factors, signalling molecules and structural proteins that may
be involved in the airways or lungs. Targets having a total context
score of 20.30 or less were ignored. Evolutionarily conserved
transcription factor binding sites within 5 kb of the miRNA start site
were determined using University of California Santa Cruz Genome
Browser (http://genome.ucsc.edu/).
Isolation and culture of human airway and lung cells
Human adult lung was obtained from AMS Biotechnology (5
donor pool from 23, 23, 26, 29 and 36 years old), and the RNA
was extracted using a modified guanidine thiocyanate technique
(Chomczynski & Sacchi, 1987). The alveolar A549 epithelial cell
line was grown in Dulbecco’s Modified Eagles Medium containing
10% fetal calf serum (FCS) and 5% L-glutamine in a humidified
chamber in 5% CO2. Prior to RNA isolation cells were washed
twice in Hanks Balanced Salt Solution and removed from the flask
using 10% Trypsin diluted in Hanks Balanced Salt Solution
incubated at 37uC. Cells were centrifuged at 1200 RCF to obtain a
Figure 6. Differential expression of highly expressed miRNAs in individual airway and lung cell populations. The expression of miRNAs
that had an expression value 10-fold or more above the average miRNA expressed in the airway, were analysed in airway biopsies, whole lung
samples, alveolar epithelial cells (A549), bronchial epithelial cells (Beas2B), airway smooth muscle (ASM), alveolar macrophages (Macs) and bronchial
fibroblasts (Fibs). The relative expression of each miRNA was calculated using the DDCT method (calibrated to the mean value of each miRNA in the
airway) generating a fold-difference in expression compared to the airways (relative expression, RU). The expression of each miRNA was attributed a
grouping according to each cell population (epithelial cells (A549s or Beas2Bs), airway smooth muscle cells (ASMCs), alveolar macrophages or
bronchial fibroblasts) or to whole airways or to a group having a wide distribution.
doi:10.1371/journal.pone.0005889.g006
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Ambion). RNA extraction was performed as described above
according to the manufacturer’s guidelines. The bronchial Beas2B
epithelial cell line was grown in Keratinocyte serum free medium
(Invitrogen) containing 5% L-glutamine, epidermal growth factor
and bovine pituitary extract (Invitrogen). Cells were recovered and
the RNA extracted as described.
Airway smooth muscle cells (ASMCs) were obtained from
human lungs (resected). Lungs were dissected to reveal the muscle
bundles, which were then remove by plucking with forceps and
placed in antibiotic-containing (penicillin and streptomycin)
Dulbecco’s Modified Eagles Medium containing 5 ml sodium
pyruvate, 5 ml MEM non essential amino acids 1006,L -
glutamine and 10% FCS (all Sigma). Explants were centrifuged
at 1200 RCF and resuspended in 25 ml of medium and incubated
at 37uC in a humidified chamber. The media was changes after 10
days and the cells grown until 75% confluent. Cells were removed
by scraping and the RNA extracted as described above. Human
alveolar macrophages were isolated using a sterile saline solution
(0.9%) (Baxter Healthcare) that was perfused through resected
lung airways from patients with lung carcinoma using a syringe
and cannula. The washout was centrifuged at 400 g for 10 min to
collect cells and re-suspended in RPMI media, before being
layered on top of a Ficoll-Paque column (Sigma-Aldrich).
Lymphocytes were harvested from the Ficoll/plasma interface
after the column had been centrifuged at 400 g for 30 min at
room temperature. The lymphocytes were washed in fresh media
before being left to adhere for 2 h in a 37uC incubator. After this
time non-adherent cells were removed and the adherent
macrophages washed with media. Cells were recovered and the
RNA was extracted as described above. Fibroblasts were extracted
from bronchial biopsies, which were collected from healthy non-
smoking volunteers undergoing bronchoscopy at Wythenshawe
Hospital, Manchester following full ethical approval and consent.
Primary human bronchial fibroblasts were isolated from bronchial
biopsies by explant culture in supplemented DMEM with
10%FCS.
Statistics
The fold-change in microRNA expression between asthmatic
and non-asthmatic airway biopsies was measured by ANOVA
using Genesis software provide by the Graz University of
Technology (Switzerland), using a p-value threshold of 0.05.
Statistical significance was validated using a two-tailed Student’s t-
test assuming unequal variance, whereby significance was
achieved for p,0.05.
Supporting Information
Table S1 Relative expression values for healthy and asthma
biopsy samples.
Found at: doi:10.1371/journal.pone.0005889.s001 (0.42 MB
DOC)
Table S2 Relative expression values for asthma biopsy samples
before and after budesonide treatment.
Found at: doi:10.1371/journal.pone.0005889.s002 (0.42 MB
DOC)
Table S3 Bioinformatic analysis of highly expressed miRNAs
expressed in airway biopsies.
Found at: doi:10.1371/journal.pone.0005889.s003 (0.05 MB
DOC)
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